A 5-year PPMI cohort analysis found that lower serum uric acid independently predicted incident depression in prodromal Parkinson’s disease (HR = 0.776; 95% CI 0.619-0.974; P = 0.029).1 The signal sits beside a lower-p-value non-motor symptom predictor: higher MDS-UPDRS Part I scores also predicted depression (HR = 1.177; 95% CI 1.093-1.267; P < 0.001). Research ...
A 2026 review of electroacupuncture for depression found a familiar split: mechanistic evidence is rich, but clinical proof remains uneven because representative trials ranged from 65 to 270 participants, used different sham or drug comparators, and often failed to connect stimulation parameters with biological endpoints.1 Electroacupuncture is plausible as a subtype-matched neuromodulation strategy, but it …
A 2026 controlled study of 96 people found severe long-COVID fatigue across 3 validated fatigue scales, but the tested peripheral inflammation, cellular-stress, neuroprotection, and autoimmunity markers did not significantly differ by group or explain fatigue severity.1 The finding argues against a simple blood-marker story, not against the reality of long-COVID fatigue. Research Highlights Fatigue was …
A 2026 biomarker study found kynurenine-pathway activation in inflammatory major depressive disorder (MDD), but not across all depression cases. Compared with non-inflammatory MDD and healthy controls, the inflammatory subgroup had higher pathway metabolites, and omega-3 treatment reduced several of them over 8 weeks.1 Research Highlights Inflammatory depression showed kynurenine activation: people with MDD and high-sensitivity …
The link between psychological stress and chronic inflammation is well-documented — what’s been less clear is which specific inflammatory proteins move with anxiety in real-world community samples. A 2026 analysis from Loomans-Kropp et al. measured a 33-marker panel in 190 minoritized and medically underserved adults from the Cancer Disparities Research Network and identified three biomarkers …
A 2026 exploratory analysis of the ABCD cancer dyspnea trial found that higher baseline cytokines predicted less placebo symptom improvement than lower baseline cytokines across 33 of 40 cytokine-symptom combinations at day 7 and 29 of 40 at day 14.1 The signal is not ready for clinical prediction, but it sharpens a trial-design problem: patients …
A 2026 PPMI analysis found that Parkinson’s patients with positive CSF α-synuclein seed amplification assay results kept gaining levodopa benefit over follow-up, while SAA-negative patients showed faster ON-medication motor progression than SAA-positive patients: 0.87 vs. 3.47 MDS-UPDRS Part III points/year in 183 matched SAA-positive and 40 SAA-negative patients.1 Research Highlights ON-state progression split sharply: SAA-positive …